转移性透明细胞肾细胞癌全身治疗反应的新兴生物标志物
Emerging Biomarkers of Response to Systemic Therapies in Metastatic Clear Cell Renal Cell Carcinoma.
作者信息
Labaki Chris, Saliby Renee Maria, Bakouny Ziad, Saad Eddy, Semaan Karl, Eid Marc, Lalani Aly-Khan, Choueiri Toni K, Braun David A
机构信息
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
出版信息
Hematol Oncol Clin North Am. 2023 Oct;37(5):937-942. doi: 10.1016/j.hoc.2023.05.021. Epub 2023 Jul 3.
Patients with metastatic clear cell renal cell carcinoma (mccRCC) experience highly heterogeneous outcomes when treated with standard-of-care systemic regimens. Therefore, valid biomarkers are needed to predict the clinical response to these therapies and help guide management. In this review, the authors outline relevant and promising biomarkers for patients with mccRCC receiving systemic therapies, with a focus on immunotherapy-based regimens.
转移性透明细胞肾细胞癌（mccRCC）患者在接受标准护理全身治疗方案时，预后差异很大。因此，需要有效的生物标志物来预测这些治疗的临床反应，并帮助指导治疗管理。在这篇综述中，作者概述了接受全身治疗的mccRCC患者相关且有前景的生物标志物，重点是基于免疫疗法的方案。
Zotero 插件